LNTH News and Press, Lantheus Holdings Inc. From 05/11/22

NORTH BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find...

NORTH BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc . (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to...

The strong launch of prostate cancer imaging agent Pylarify will aid in generating nearly double revenues in fiscal 2022, states B. Riley analyst Justin Walsh. Analyst further believes that the Lantheus (LNTH) -11% is well-positioned in the rapidly growing radiopharmaceutical space....

Lantheus Holdings (NASDAQ: LNTH) , which makes diagnostic medical imaging agents that help physicians diagnose and treat cardiovascular and other diseases, saw its shares rise 16.4% on Friday. The stock closed on Thursday at $59.12, then opened on Friday at $68.65, rising to its 52-...

Lantheus Holdings, Inc. (LNTH) Q1 2022 Results Earnings Conference Call April 29, 2022, 08:00 AM ET Company Participants Mark Kinarney - Senior Director, Investor Relations Mary Anne Heino - President and Chief Executive Officer Paul Blanchfield - Chief Commercial Officer Robert Marshall Jr. ...

Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...

Lantheus Holdings (NASDAQ:LNTH), a supplier of diagnostic products, has added ~18% in the pre-market Friday after the company beat Street forecasts with its 1Q 2022 financials and set the 2022 outlook ahead of the consensus. The company's worldwide revenue for the quarter grew ~126% YoY to ~$...

GTY Technology (GTYH) +119% as investment firm agrees to pay 123% premium in taking the company private. Finch Therapeutics (FNCH) +63% as FDA lifts clinical hold on antibacterial drug. Zymeworks (ZYME) +47% on $10.50/share takeover bid. Lantheus Holdings (LNTH)&...

The following slide deck was published by Lantheus Holdings, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Lantheus Holdings, Inc. 2022 Q1 - Results - Earnings Call Presentation

Lantheus press release (NASDAQ:LNTH): Q1 Non-GAAP EPS of $0.97 beats by $0.51. Revenue of $208.9M (+125.8% Y/Y) beats by $43.6M. Guidance: 2Q22 Revenue between $200M-$215M vs consensus $178.95M. Adj. EPS between $0.67-$0.73 vs consensus of $0.50 FY22 Revenue between $800M-$835M vs consensus $...